Treatment of supratentorial glioblastoma multiforme with radiotherapy and a combination of BCNU and tamoxifen: a phase II study.
作者： Massimo Napolitano , Florence Keime-Guibert , Annick Monjour , Catherine Lafitte , Alain Ameri
关键词: Tamoxifen 、 Carmustine 、 Toxicity 、 Gastroenterology 、 Phases of clinical research 、 Thrombosis 、 Venous thrombosis 、 Standard treatment 、 Chemotherapy 、 Surgery 、 Medicine 、 Internal medicine
摘要: From May 1990 to November 1994, 70 consecutive patients suffering from glioblastoma multiforme were treated following surgery with conventional radiotherapy and adjuvant IV BCNU administered alone or in combination tamoxifen. Twenty-five received (control group A) while 24 also 40 mg of tamoxifen (TMX) PO daily (group B) 21 100 TMX C). There no significant differences between the 3 groups concerning age, type resection median post-operative Karnofsky performance status (KPS). Blood toxicity over grade II occurred 33.5% receiving versus 12% (p < 0.05). Deep venous thrombosis complications observed 4 each group, whereas they not control 0.04). Median time tumor progression (MTTP) was 35 weeks 27 both B C. survival (MST) 56, 66 51 weeks, respectively. These results suggest that addition standard treatment glioblastomas does affect overall but may increase risk deep nitrosourea-induced blood toxicity.
springer.com
sci-hub.se 参考文章(45)
Barnett M, Sternson L, Fabian C, Clinical pharmacology of tamoxifen in patients with breast cancer: comparison of traditional and loading dose schedules. Cancer treatment reports. ,vol. 64, pp. 765- ,(1980)
J V Kemp, J S Patterson, H K Adam, Studies on the metabolism and pharmacokinetics of tamoxifen in normal volunteers. Cancer treatment reports. ,vol. 64, pp. 761- 764 ,(1980)
Kieran Horgan, Eryl Cooke, Maurice B. Hallett, Robert E. Mansel, Inhibition of protein kinase C mediated signal transduction by tamoxifen Biochemical Pharmacology. ,vol. 35, pp. 4463- 4465 ,(1986) , 10.1016/0006-2952(86)90764-1
Ralf F. Pettersson, A. Jonas Ekstrand, C. David James, V. Peter Collins, V. Peter Collins, Barbara Seliger, Webster K. Cavenee, Genes for Epidermal Growth Factor Receptor, Transforming Growth Factor α, and Epidermal Growth Factor and Their Expression in Human Gliomas in Vivo Cancer Research. ,vol. 51, pp. 2164- 2172 ,(1991)
Susan M. Chang, Fred G. Barker II, Stephen L. Huhn, M. Kelly Nicholas, Margaretta Page, Jane Rabbitt, Michael D. Prados, High dose oral tamoxifen and subcutaneous interferon alpha-2a for recurrent glioma Journal of Neuro-oncology. ,vol. 37, pp. 169- 176 ,(1998) , 10.1023/A:1005826323652
N F Fritz, D C Tormey, V C Jordan, Long-term adjuvant therapy with tamoxifen: effects on sex hormone binding globulin and antithrombin III. Cancer Research. ,vol. 47, pp. 4517- 4519 ,(1987)
Randolph D. Christen, Jeffrey A. Jones, Kathleen D. Albright, Stephen B. Howell, Edward F. Mc Clay, Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells. Cancer Research. ,vol. 53, pp. 1571- 1576 ,(1993)
K I Pritchard, A H Paterson, S Fine, N A Paul, B Zee, L E Shepherd, H Abu-Zahra, J Ragaz, M Knowling, M N Levine, S Verma, D Perrault, P L Walde, V H Bramwell, M Poljicak, N Boyd, D Warr, B D Norris, D Bowman, G R Armitage, H Weizel, R A Buckman, Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group. Journal of Clinical Oncology. ,vol. 15, pp. 2302- 2311 ,(1997) , 10.1200/JCO.1997.15.6.2302
R M Liskamp, C A O'Brian, I B Weinstein, D H Solomon, Inhibition of protein kinase C by tamoxifen. Cancer Research. ,vol. 45, pp. 2462- 2465 ,(1985)
A. A. Surnock, C. M. Degiorgio, M. L. J. Apuzzo, L. Masri, L. P. Weiner, D. R. Hinton, W. T. Couldwell, M. H. Weiss, R. E. Law, Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. Clinical Cancer Research. ,vol. 2, pp. 619- 622 ,(1996)